Teva Pharmaceutical Industries ROA 2010-2024 | TEVA

Current and historical return on assets (ROA) values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Teva Pharmaceutical Industries ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-09-30 $-0.96B $41.76B -2.26%
2024-06-30 $-0.45B $41.34B -1.07%
2024-03-31 $-0.48B $42.77B -1.12%
2023-12-31 $-0.56B $43.48B -1.30%
2023-09-30 $-2.34B $42.09B -5.42%
2023-06-30 $-2.35B $43.10B -5.38%
2023-03-31 $-1.71B $43.46B -3.85%
2022-12-31 $-2.45B $44.01B -5.40%
2022-09-30 $-1.29B $44.25B -2.79%
2022-06-30 $-1.05B $45.93B -2.24%
2022-03-31 $-0.62B $47.06B -1.28%
2021-12-31 $0.42B $47.67B 0.86%
2021-09-30 $0.73B $47.85B 1.48%
2021-06-30 $-3.92B $49.20B -7.89%
2021-03-31 $-3.98B $49.00B -7.79%
2020-12-31 $-3.99B $50.64B -7.57%
2020-09-30 $-4.03B $49.74B -7.41%
2020-06-30 $0.00B $54.99B 0.01%
2020-03-31 $-0.83B $55.33B -1.44%
2019-12-31 $-1.00B $57.47B -1.71%
2019-09-30 $-4.05B $57.25B -6.83%
2019-06-30 $-4.01B $59.42B -6.54%
2019-03-31 $-3.56B $59.85B -5.64%
2018-12-31 $-2.40B $60.68B -3.66%
2018-09-30 $-11.06B $65.06B -16.27%
2018-06-30 $-10.26B $67.03B -14.01%
2018-03-31 $-16.05B $69.18B -20.56%
2017-12-31 $-16.53B $70.62B -19.77%
2017-09-30 $-5.96B $86.08B -6.69%
2017-06-30 $-6.15B $86.36B -6.65%
2017-03-31 $0.08B $91.28B 0.09%
2016-12-31 $0.07B $93.06B 0.09%
2016-09-30 $1.59B $98.75B 2.39%
2016-06-30 $1.35B $57.92B 2.49%
2016-03-31 $1.70B $55.13B 3.26%
2015-12-31 $1.57B $54.23B 3.14%
2015-09-30 $1.78B $48.63B 3.69%
2015-06-30 $2.55B $50.37B 5.35%
2015-03-31 $2.76B $46.95B 5.91%
2014-12-31 $3.06B $46.42B 6.55%
2014-09-30 $2.75B $46.61B 5.85%
2014-06-30 $2.58B $46.73B 5.47%
2014-03-31 $1.38B $46.89B 2.92%
2013-12-31 $1.27B $47.51B 2.66%
2013-09-30 $1.21B $47.85B 2.49%
2013-06-30 $0.42B $47.50B 0.86%
2013-03-31 $1.73B $48.07B 3.52%
2012-12-31 $1.96B $50.61B 3.94%
2012-09-30 $2.15B $49.58B 4.32%
2012-06-30 $3.14B $48.88B 6.59%
2012-03-31 $2.86B $50.47B 6.28%
2011-12-31 $2.76B $50.14B 6.46%
2011-09-30 $3.02B $41.28B 7.62%
2011-06-30 $3.16B $40.16B 8.07%
2011-03-31 $3.38B $39.25B 8.91%
2010-12-31 $3.33B $38.15B 9.10%
2010-09-30 $2.94B $39.04B 8.27%
2010-06-30 $2.54B $35.19B 7.45%
2010-03-31 $2.26B $34.05B 6.78%
2009-12-31 $2.00B $33.81B 6.08%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.044B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00